Evaluation of the efficacy of daikenchuto (TJ -100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial  by Okada, Ken-ichi et al.
Funded
tion Ne
mura &
Accepte
Reprint
of Surge
641-851Evaluation of the efficacy of
daikenchuto (TJ -100) for the
prevention of paralytic ileus after
pancreaticoduodenectomy: A
multicenter, double-blind,
randomized, placebo-controlled trial
Ken-ichi Okada, MD,a Manabu Kawai, MD,a Seiko Hirono, MD,a Tsutomu Fujii, MD,b
Yasuhiro Kodera, MD,b Masayuki Sho, MD,c Yoshiyuki Nakajima, MD,c Sohei Satoi, MD,d
A-Hon Kwon, MD,d Yasuhiro Shimizu, MD,e Yoshiyasu Ambo, MD,f Naru Kondo, MD,g
Yoshiaki Murakami, MD,g Jiro Ohuchida, MD,h Hidetoshi Eguchi, MD,i Hiroaki Nagano, MD,i
Mari S. Oba, PhD,j Satoshi Morita, PhD,k Junichi Sakamoto, MD,l and Hiroki Yamaue, MD,a the
JAPAN-PD Investigators, Wakayama, Nagoya, Kashihara, Hirakata, Sapporo, Hiroshima, Miyazaki, Osaka,
Yokohoma, Kyota, and Kakamigahara, Japan
Background. We assessed the efficacy of TJ-100 taken perioperatively to recovery among patients with
periampullary tumor or tumor of the head of the pancreas who underwent pancreaticoduodenectomy (PD).
Patients and methods. In this multicenter, randomized, double-blinded, placebo-controlled, phase II trial
(JAPAN-PD Study), patients were assigned randomly in a 1:1 ratio to receive TJ-100 or placebo. The
coprimary endpoints were (1) incidence of postoperative paralytic ileus lasting >72 hours after surgery
and (2) time to occurrence of postoperative paralytic ileus. This trial is registered at the UMIN Clinical
Trials Registry (000007975) and at ClinicalTrials.gov (NCT01607307).
Results. From August 2012 through July 2013, we assessed 273 patients for eligibility, and 224
underwent randomization; 112 patients received TJ-100, and 112 patients received placebo. The
population for analysis consisted of 104 patients who received TJ-100 and 103 who received placebo.
Paralytic ileus occurred 35 (33.7%) in the TJ-100 group and 38 (36.9%) in the placebo group
(P = .626). Time to first flatus was 2.25 (2.00–2.50) days in the TJ-100 group and 2.50 (1.50–2.50)
days in the placebo group (P = .343). Among 23 patients who underwent a pylorus ring–preserving PD,
time to first flatus was lower in the TJ-100 group than in the placebo group: 0.50 (0.50–1.00) days versus
1.50 (0.50–3.00) days (P = .034).
Conclusion. Ourfindings suggest that use of TJ-100 didnot improve recovery fromparalytic ileus after PD, and
may preclude the routine use of TJ-100 in clinical practice after PD operation. (Surgery 2016;159:1333-41.)From the Second Department of Surgery,a Wakayama Medical University, Wakayama; Department of
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1334 Okada et alPANCREATICODUODENECTOMY (PD) is a multiorgan
operative procedure with a high incidence of
morbidity1-3 among patients with periampullary
disease. Postoperative paralytic ileus after abdom-
inal surgery is a common/uncomfortable compli-
cation and is recognized as an inevitable
response to intraperitoneal surgery.4-6 Recently,
several studies have reported that a fast-track recov-
ery program decreases the incidence of morbidity
and the duration of the postoperative hospital
stay among patients undergoing PD.7 The systemic
rehabilitation can increase the intra-abdominal
pressure, which would promote bowel peristalsis
and the passage of flatus. Maintenance of bowel
motility is essential for favorable fast-track recovery
from postoperative paralytic ileus. The evidence
for paralytic ileus depends on the observations
that abdominal distention occurs often in the im-
mediate postoperative period, bowel sounds are
not heard, and passage of flatus or stool is delayed
for several days.8 A past study chose to use to
examine as parameters the relationship of bowel
sounds and the time to first flatus as gastrointes-
tinal function.9
Daikenchuto (TJ-100), a traditional Japanese
herbal medicine, has been used widely for the
prevention and treatment of postoperative
ileus.10-13 TJ-100 extract powder is manufactured
by Tsumura & Co. (Tokyo, Japan) as an aqueous
extract containing 2.2% Japanese pepper, 5.6% pro-
cessed ginger, 3.3% ginseng, and 88.9% maltose
syrup powder. Previous pharmacologic studies sug-
gest that acetylcholine released from intrinsic
cholinergic nerves and tachykinins from sensory
neurons are involved in the contractions induced
by sansyo (hydroxy b-sanshool), which is the main
ingredient of TJ-100.14 Tsumura & Co. submitted
an IND (Investigational New Drug Application) of
TJ-100 to the U.S. Food and Drug Administration
(FDA). The drug has been approved by the FDA
as an investigational drug, and many placebo-
controlled double-blinded trials have been
launched in the United States to investigate its
use for postoperative ileus (NCT02232893,
NCT00266461, NCT00871325), constipation
(NCT01139216, NCT01348152), irritable bowel syn-
drome (NCT01890837, NCT02074579), and Crohn
disease (NCT01388933).15
Despite the widespread and common use of TJ-
100 in Japanese clinical practice, its impact on the
normalization of bowel peristalsis after PD remains
unclear in the prospective study, and whether this
traditional Japanese herbal medicine actually
makes a difference in postoperative paralytic ileus
in the setting of modern perioperativemanagement remains controversial. The results
of our previous prospective cohort study (UMIN-
CTR ID no. 000005056) indicated that periopera-
tive administration of TJ-100 decreases paralytic
ileus substantially after PD and that the time to
first postoperative flatus occurs substantially earlier
in patients who receive perioperative TJ-10014;
however, the previous study was neither placebo-
controlled nor randomized/blinded, and there is
a limitation because of the small number of cases.
To confirm the results of the cohort study, we con-
ducted a multicenter, randomized, placebo-
controlled phase II trial (JAPAN-PD Study) of
TJ-100 to evaluate whether perioperative adminis-
tration of TJ-100 reduces the incidence of postop-
erative paralytic ileus after PD.
PATIENTS AND METHODS
Study oversight and author contributions. The
JAPAN-PD study is a multicenter, randomized,
double-blinded, placebo-controlled, phase II trial
conducted at 9 high-volume centers for pancreatic
surgery certified by the Japanese Society of
Hepato-Biliary-Pancreatic Surgery. The trial was
approved by the institutional review board of
each participating institution. This trial is regis-
tered at the UMIN Clinical Trials Registry (no.
000007975) and at ClinicalTrials.gov (no.
NCT01607307). An independent data and safety
monitoring board provided regulatory oversight
by reviewing concealed patient data annually.
The data and safety monitoring board also con-
ducted a prespecified interim analysis after the
enrollment of 224 patients who had been
confirmed to be eligible for the study. The study
was designed and initiated by the academic investi-
gators and was funded by the Epidemiological and
Clinical Research Information Network. Em-
ployees of Tsumura & Co. did not have access to
the data during the trial, did not participate in
the data analysis, and did not participate in the
preparation of the manuscript.
Patients. Eligible patients enrolled in this study
were adults ($20 years of age) who were scheduled
to undergo PD for periampullary tumors and
tumors of the head of the pancreas.16 The
following types of patients were excluded: patients
with tumors that required resection of the colon;
patients who were expected to have severe intra-
abdominal adhesions as the result of previous
surgery or peritonitis; patients who had used
gastrointestinal prokinetic medication, antipsy-
chotic medication, or antidepressants; and patients
who had used Japanese herbal (Kampo) medicines
within 4 weeks before registration.16 Accelerated
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participating 9 centers.
Randomization and study protocol. Randomiza-
tion was carried out according to the previously
published protocol paper.16 The type of primary
disease, the presence of neoadjuvant therapy, the
presence of the pylorus ring of the remnant stom-
ach, and the presence of the postoperative enteral
alimentation were determined as balancing sub-
groups. Patients were enrolled ultimately from 9
high-volume centers that submitted case report
forms without any protocol violation. After
providing written informed consent, patients
were assigned randomly in a 1:1 ratio to receive
TJ-100 or placebo. A solution of 5 g of TJ-100 or
placebo was administered orally 3 times daily
(15 g/day) immediately before meals or every
8 hours for 17 consecutive days (from preoperative
day 3 to postoperative day 14), except on the oper-
ative day and on postoperative day 1; on the oper-
ative day, TJ-100 or placebo was administered
immediately after the operation in a single 5-g
dose as a diluent via a delivering tube (10 Fr) in-
serted into jejunum; and on postoperative day 1,
3 doses of 5 g were delivered via a delivering
tube to prevent aspiration pneumonia.16 We pro-
hibited the combination use with gastrointestinal
prokinetic medication, antipsychotic medication,
or antidepressants by the protocol of this study. Se-
prafilm Adhesion Barrier Genzyme Corporation,
Cambridge, MA and epidural analgesia were used
at the discretion of each institution.17,18
Primary and secondary endpoints. In this clin-
ical trial, the coprimary endpoints were (1) inci-
dence of postoperative paralytic ileus lasting
>72 hours after surgery and (2) time to occur-
rence of postoperative paralytic ileus. Postopera-
tive paralytic ileus was defined as delay of the first
postoperative flatus lasting for >72 hours
(3.0 days) after surgery based on the description
about the definition of paralytic ileus in the pre-
vious literature,4,5 or some other status requiring
intervention for treatment for ileus; 12 hours was
counted as 0.5 postoperative day, and 24 hours as
1.0 postoperative day. The secondary endpoints
were the incidence of postoperative paralytic ileus
in cases which combined with/without enteral
alimentation, quality of life (QOL) assessment by
the Gastrointestinal Symptom Rating Scale Score
(Japanese version), assessment of abdominal pain
and abdominal distention by means of a visual
analog scale, the ratio of the abdominal circumfer-
ence on postoperative day 3 to the circumference
on the operative day immediately after surgery,
the incidence of postoperative complications, theduration of the postoperative hospital stay, the
incidence of surgical-site infection, and the inci-
dence of postoperative small bowel obstruction
within 2 years after surgery.
Adverse events and dose modifications. Toxic-
ities and adverse events were evaluated by the
National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE) ver. 4.0. The
criteria for dose reduction and discontinuation of
the protocol treatment were as follows. In cases in
which grade 2 postoperative diarrhea or other
clinical adverse event was observed, the dose of
the TJ-100 or the placebo was reduced to 2.5 g, and
in case of grade 3 postoperative diarrhea or other
clinical adverse event was observed, the protocol
treatment was terminated.16
Drain placement and drainage fluid collection.
Drains were placed surgically into the foramen of
Winslow and intraperitoneal space around the
pancreaticoenterostomy in all of the patients who
received TJ-100 and placebo according to the study
protocol. The drainage fluid was collected and
examined for amylase level on postoperative day 1,
3, and 4 to evaluate pancreatic fistula.
Measurement of serum and drainage cytokine
concentrations. Serum and drainage were ob-
tained on postoperative days 1 and 3 for a multiple
cytokine assay. The 27 measured cytokines, the
methods of measurement, and the sensitivity level
for each cytokines were similar to those previously
reported.14
Complications. All morbidities, the global
morbidity rate, and the type of complications
were evaluated by means of the classification of
Dindo.19 Postoperative delayed gastric emptying
(DGE), postoperative pancreatic fistula, and intra-
abdominal hemorrhage were interpreted to the
classification of Dindo based on the consensus defi-
nition and the clinical grading of DGE proposed by
the International Study Group of Pancreatic Sur-
gery,20 the International Study Group of Pancreatic
Fistula guidelines,21 and the International Study
Group of Pancreatic Surgery definition of intra-
abdominal hemorrhage.22 Surgical-site infections
included surgical wound or intra-abdominal ab-
scesses with positive cultures. Mortality was defined
as all deaths related to surgery.
Statistical analysis. Sample-size calculation and
statistical considerations were predefined in the
protocol paper16 of this study previously published
in The Japanese Journal of Clinical Oncology as follows:
the multiplicity issue (inflation of the type I error)
as the result of analyzing 2 endpoints was ad-
dressed with the Bonferroni method. That is, the
significance levels for both tests are set at 2.5% to
Fig. Enrollment and randomization.
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size was calculated on the basis that the incidence
rate of postoperative paralytic ileus for 72 hours af-
ter surgery was expected to be 90% for the placebo
group. The expected value of 90% for the placebo
group was expected on the basis of the result of the
control group in our previous study.14 In the event
the effect of decreasing the incidence of postoper-
ative paralytic ileus is assumed to be 20% for the
TJ-100 group, the least number of patients to pro-
vide the 85% power necessary to confirm the supe-
riority of a group was calculated to be 94 per group
for a 2-sided 2.5% significance level test. Further-
more, given the number of patients, an 84% statis-
tical power was retained to prove the superiority in
terms of time to occurrence of postoperative para-
lytic ileus for the hazard ratio of 0.62. The signifi-
cance level for this inference also was set at 2.5%.
Taking an exclusion from analysis of approxi-
mately 15% into account, we set the number of pa-
tients to be accrued at 110 per treatment arm (220
in total). A heterogeneous subgroup of patients
were adjusted by central randomization to either
Arm A (TJ-100) or Arm B (placebo) by the use of
primary disease, implementation of any kind of
preoperative therapy, preservation of pylorus ring
in the remnant stomach, the presence of enteral
alimentation, and the institution as dynamic
balancing variables.
Statistical comparisons between 2 groups were
made by means of the chi-square statistic, the
Fisher exact test, or the Mann-Whitney U test,
where appropriate. The risk factors for paralytic
ileus were explored by means of a univariate logis-
tic regressions model and a multivariate logistic
regression model by use of the stepwise selection
method (criteria for variable entry and stay into
the model were P = .2 and P = .3, respectively).
Odds ratios (ORs) and their 95% confidence inter-
vals (CIs) were used to express the contributions of
factors. Statistical significance was defined as
P< .05. Median time to first flatus was estimated
with Kaplan-Meier method. Group differences
were assessed by log-rank test. Relative risk was esti-
mated with the Cox proportional hazards model,
and the relative risk smaller than 1 favored TJ-
100. With respect to the primary endpoints, the sig-
nificant levels were 0.025 for each primary
endpoint, because this study set two primary end-
points. All the analyses were performed using
SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Patient characteristics. From August 2012
through July 2013, 273 patients were assessed foreligibility. Of those, 41 cases were excluded by the
exclusion criteria, 4 cases were claimed to be
ineligible, and 4 patients declined to participate,
leaving 224 patients who were assigned randomly
to the TJ-100 group (112 patients) or the placebo
group (112 patients). In the TJ-100 group, 3
patients (2.7%) did not meet the criteria to take
the test medications according to the protocol; 1
patient (0.9%) withdrew consent; and 4 patients
(3.6%) did not undergo PD because of inoperable
findings (hepatic metastasis [N = 1] and para-
aortic lymph node metastasis [N = 1]), conversion
to total pancreatectomy [N = 1], and cancellation
because of a diagnosis with tuberculosis [N = 1].
These 8 patients were excluded from the analyses.
In the placebo group, 9 patients (8.0%) did not
undergo PD because of inoperable findings (peri-
toneal metastasis [N = 1], para-aortic metastasis
[N = 2], and hepatic metastasis [N = 2]), positive
cytology for ascites [N = 1], conversion to total
pancreatectomy [N = 1], conversion to central
pancreatectomy [N = 1], and conversion to enucle-
ation of the tumor [N = 1]. These 9 patients were
excluded. Therefore, the population for primary
analysis consisted of 104 patients who received
TJ-100 and 103 who received placebo (Fig). PD
combined with portal vein resection was per-
formed in 7 patients (6.7%) in the TJ-100 group
and 8 (7.8%) in the placebo group (P = .774)
(Table I). No patients underwent PD with artery
combined resection in this study.
Baseline compliance with completion of Gastro-
intestinal Symptom Rating Scale questionnaires
was high: in the TJ-100 group, 102 preoperative
questionnaires (98.1%) and 100 postoperative
questionnaires (96.2%) were completed, and in
the placebo group, the corresponding values were
Table I. Baseline and operative characteristics of patients*
Characteristic TJ-100 (N = 104) Placebo (N = 103) P value
Baseline
Male sex 49 (47.1) 38 (36.9) .136
Age, y 68.9 ± 8.4 64.9 ± 11.3 .004
BMI, kg/m2 22.1 ± 3.0 22.4 ± 3.4 .494
Comorbidity 23 (22.1) 29 (28.2) .340
Past abdominal operative history 45 (43.3) 32 (31.1) .085
Pancreatic cancer 60 (57.7) 59 (57.3) .952
Neoadjuvant therapy 19 (18.3) 21 (20.4) .699
History of disease
Diabetes mellitus 19 (18.3) 22 (21.4) .577
Brain infarction 5 (4.8) 2 (1.9) .445
Hypertension 23 (22.1) 23 (22.3) .970
Atrial fibrillation 3 (2.9) 2 (1.9) .999
Ischemic heart disease 4 (3.8) 4 (3.9) .999
Operative
Epidural anesthesia 62 (59.6) 65 (63.1) .606
Operative time, min 419 ± 103 405 ± 110 .195
Blood loss, mL 764 ± 641 729 ± 701 .262
Pylorus-ring-preserving 11 (10.6) 12 (11.7) .806
Reconstruction
C-P-G 0 (0.0) 1 (1.0) .797
P-C-G 92 (88.5) 90 (87.4)
G-P-C or G-C-P 1 (1.0) 1 (1.0)
Other 11 (10.6) 11 (10.7)
Use of Seprafilm 68 (65.4) 74 (71.8) .317
Lymph node dissection
D0 2 (1.9) 2 (1.9) .611
D1 12 (11.5) 8 (7.8)
D2 90 (86.5) 92 (89.3)
D3 0 (0.0) 1 (1.0)
Dissection of nerve plexus around the SMA
Not done 51 (49.0) 44 (42.7) .404
Done 53 (51.0) 59 (57.3)
Portal vein resection
Not done 97 (93.3) 95 (92.2) .774
Done 7 (6.7) 8 (7.8)
Postoperative hospital stay, daysy 20 (18.0–23.0) 19.5 (18.0–22.0) .708
*Values are mean ± standard deviation or number (percentage), unless otherwise stated.
yMedian (95% confidence interval).
BMI, Body mass index; C-P-G, reconstruction with jejunum from choledochus, pancreas, to stomach in order; G-C-P, reconstruction with jejunum from
stomach, choledochus, to pancreas in order; G-P-C, reconstruction with jejunum from stomach, pancreas, to choledochus in order; P-C-G, reconstruction
with jejunum from pancreas, choledochus, to stomach in order; SMA, superior mesenteric artery.
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completion of visual analog scale questionnaires
was also high: 101–104 questionnaires (97.1–
100.0%) and 100–102 questionnaires (97.1–
99.0%) in the TJ-100 and placebo groups,
respectively.
Except for age distribution, the preoperative
and operative characteristics of the patients were
similar in the 2 groups (Table I). The criteria for
dose reduction and discontinuation of the proto-
col treatment were met by 35 patients (33.7%) in
the TJ-100 group and 30 patients (29.1%) in theplacebo group (P = .483). These patients, who
experienced grade 2 or 3 postoperative diarrhea
or other clinical adverse events (CTCAE ver. 4.0
criteria), were administered a decreased dose of
the test drug or the placebo (2.5 g) or were imme-
diately discontinued the treatment in accordance
with the treatment protocol.
Study outcomes. The coprimary endpoint, ie,
postoperative paralytic ileus was met in 73 (32.6%)
of the 224 randomized patients (Table II): 35 pa-
tients (33.7%) in the TJ-100 group and 38 patients
(36.9%) in the placebo group (risk difference (%),
Table II. Study endpoints
Coprimary endpoint TJ-100 (N = 104) Placebo (N = 103) P value
Postoperative paralytic ileus, n (%) 35 (33.7) 38 (36.9) .626
Time to first postoperative flatus* 2.25 (2.00–2.50) 2.50 (1.50–2.50) .343
First solid meal (postoperative day)y 5.8 ± 7.4 4.8 ± 2.1 .200
Tube insertion for paralytic ileus, n (%) 1 (1.0) 1 (1.0) .999
Administration of other medications for paralytic ileus, n (%)z 2 (1.9) 1 (1.0) .999
*Median (97.5% confidence interval).
yMean ± standard deviation.
zAdministration of other drugs to improve bowel motility.
Table III. Postoperative complications
Complications
TJ-100
(N = 104)
Placebo
(N = 103)
P
value
Postoperative pancreatic fistula,* n (%)
I 18 (17.3) 15 (14.6) .846
II 0 (0.0) 0 (0.0)
IIIa 10 (9.6) 16 (15.5)
IIIb 2 (1.9) 0 (0.0)
IVa 0 (0.0) 0 (0.0)
IVb 0 (0.0) 0 (0.0)
V 0 (0.0) 0 (0.0)
Delayed gastric emptying,* n (%)
I 3 (2.9) 9 (8.7) .645
II 7 (6.7) 5 (4.9)
IIIa 2 (1.9) 0 (0.0)
IIIb 0 (0.0) 0 (0.0)
IVa 0 (0.0) 0 (0.0)
IVb 0 (0.0) 0 (0.0)
V 0 (0.0) 0 (0.0)
Aspiration
pneumonia, n (%)
1 (1.0) 0 (0.0) .999
Surgical-site
infection, n (%)
Wound infection 5 (4.8) 4 (3.9) .744
Intraperitoneal
abscess
7 (6.7) 14 (13.6) .102
Mortality, n (%) 0 (0.0) 1 (1.0) .498
*Postoperative pancreatic fistula and postoperative delayed gastric
emptying (DGE) were interpreted by the classification of Dindo based
on the consensus definition and the clinical grading of the International
Study Group of Pancreatic Fistula guidelines and DGE proposed by the
International Study Group of Pancreatic Surgery.
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to the other coprimary endpoint, the time to first
flatus was median 2.25 (2.00–2.50) days in the TJ-
100 group and 2.50 (1.50–2.50) days in the pla-
cebo group (relative risk, 1.12; 97.5% CI, 0.82–
1.53; P = .343). These results indicate that treat-
ment with TJ-100 did not decrease greatly the
risk of postoperative paralytic ileus. Although
only 3 patients (less than 2% of each group)
received other medications to rescue the condition
of severe paralytic ileus after the judge point of
72 hours postoperatively, there were no differences
between the 2 groups with regard to the incidence
of additional therapy for paralytic ileus, including
insertion of a tube into the stomach or jejunum
or administration of other drugs to improve bowel
motility (Table II).
With regard to the incidence of paralytic ileus, a
comparison between the TJ-100 and placebo
groups revealed similar findings for the following
prespecified subgroups: with or without neoadju-
vant therapy, a pylorus ring–preserving PD (PPPD)
versus a pylorus-resecting PD, and pancreatic
carcinoma versus other types of primary disease.
There also were no substantial differences in
time to first flatus among the following subgroups:
with or without neoadjuvant therapy, a PPPD
versus a pylorus-resecting PD, and pancreatic
carcinoma versus other types of primary disease.
In contrast, among the 23 patients who underwent
PPPD, the time to first flatus was substantially less
in the TJ-100 group than in the placebo group:
0.50 (0.50–1.00) days versus1.50 (0.50–3.00) days,
respectively (relative risk, 0.46; 95% CI, 0.19–1.13;
P = .034). Otherwise, no differences were demon-
strated in the other subgroups on the basis of
age, sex, presence/absence of Grade B or C
pancreatic fistula, and institution.
Postoperative complications. Table III shows the
postoperative complications in patients in the
TJ-100 and placebo groups. The incidence of post-
operative complications revealed no substantial
differences between the 2 groups. One patient in
the placebo group died from acute respiratorydistress syndrome on postoperative day 50; in the
TJ-100 group, there were no deaths or reopera-
tions related to surgery.
Adverse events. The overall postoperative mor-
tality was 0.5% (1 death in the placebo group).
The overall rate of grade 3 and 4 events (CTCAE
ver. 4.0 criteria) at 60 days was 9.7%: 12 patients
(11.5%) in the TJ-100 group and 8 patients (7.8%)
in the placebo group had grade 3 or 4 adverse
events. The majority of these adverse events
represented expected diarrhea or postoperative
abnormalities in the results of serum chemical
analyses.
Table IV. Univariate and multivariate analyses: risk factors for paralytic ileus
Variable
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Group, TJ-100/placebo 0.87 0.49 1.54 .626
Sex, male/female 1.38 0.77 2.48 .279
Age, $68/<68 y 1.04 0.59 1.85 .884
BMI, kg/m2, $22/<22 0.84 0.47 1.48 .544
Past abdominal operative history, yes/no 1.41 0.79 2.54 .248
Neoadjuvant therapy, yes/no 0.75 0.35 1.57 .439
Epidural anesthesia, yes/no 1.61 0.88 2.94 .121 2.35 1.20 4.59 .012
Operative time, min, $409/<409 1.53 0.86 2.71 .149
Blood loss, mL, $500/<500 1.51 0.85 2.71 .162 1.57 0.85 2.90 .153
Pylorus ring–preserving, yes/no 0.47 0.17 1.33 .157
Use of Seprafilm, yes/no 1.65 0.87 3.13 .125 2.61 1.27 5.36 .009
Lymph node dissection, D2 or 3/D0 or 1 1.10 0.45 2.71 .833 2.14 0.76 6.01 .148
Dissection of nerve plexus around the SMA, yes/no 0.68 0.38 1.21 .190 0.52 0.27 1.00 .051
Enteral alimentation, yes/no 2.39 0.62 9.19 .205 2.50 0.61 10.30 .205
BMI, Body mass index; CI, confidence interval; OR, odds ratio; SMA, superior mesenteric artery.
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There was no substantial difference between the
2 groups with regard to QOL as assessed by the
Gastrointestinal Symptom Rating Scale Score: acid
reflux (P = .690), abdominal pain (P = .818), indi-
gestion (P = .900), diarrhea (P = .336), constipa-
tion (P = .495), and the sum of all the categories
(P = .652). There were also no differences with re-
gard to visual analog scale assessment of abdom-
inal pain (P = .296) and abdominal distention
(P = .969) or with regard to the ratio of abdominal
circumference on postoperative day 3 to that on
the operative day just after surgery (P = .320).
Risk factors for paralytic ileus. In univariate
analyses, the following factors showed moderate
association with paralytic ileus: epidural anes-
thesia, operative time, blood loss, PPPD, the use
of a hyaluronic acid-carboxymethylcellulose mem-
brane (Seprafilm) for adhesion prevention, and
dissection of nerve plexus around the superior
mesenteric artery. Multivariate analysis revealed
that the epidural anesthesia (OR, 2.35; 95% CI,
1.20–4.59; P = .012) and use of Seprafilm
(OR, 2.61; 95% CI, 1.27–5.36; P = .009) were inde-
pendent risk factors for paralytic ileus even after
we controlled for the other variables (Table IV).
Cytokine concentrations in drainage and serum.
The 2 groups showed no differences in the
concentrations of 27 cytokines in the drainage
and serum (data not shown).
DISCUSSION
The results of this multicenter, double-blind,
randomized, placebo-controlled trial showed thatperioperative treatment with TJ-100 neither
decreased the incidence of clinically relevant post-
operative paralytic ileus nor shortened the time to
first postoperative flatus. TJ-100 does not seem as
relevant for surgeons in Western countries,
including the United States, whereas it is used
commonly in Asian countries. TJ-100, however, is
now under clinical development in the United
States as a drug to improve postoperative paralysis
and QOL after hospital discharge, as commonly
accepted in Japan. In United States, 4 clinical
pharmacology studies and 2 early phase II studies
have been completed. At present, a study to verify
the efficacy against abdominal complaints accom-
panying irritable bowel syndrome and a study to
demonstrate recovery of intestinal functions and
early improvement of abdominal symptoms after
laparoscopic colectomy are ongoing. When these
clinical studies have been finished, it is expected
that TJ-100 will be approved as a prescription drug
by the FDA in the near future, and it will be
expected that the American doctors in the gastro-
enterological surgery field will use this drug in the
clinical practice.
This compound apparently is used often in
Asia-Pacific countries but has not been incorpo-
rated into practice in Western countries. Previous
trials investigating the effect of TJ-100 after total
gastrectomy, however, demonstrated that TJ-100
greatly shortens the time to first bowel movement.
Therefore, the impact of this compound might
spread in Western countries.10,15 In the present
study, among the small subgroup of patients who
underwent PPPD, the first flatus was detected
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placebo group. The pylorus-resecting PD is the
most commonly used procedure in Japan, because
denervation and devascularization of the pylorus
ring lead to DGE.23 Globally, however, PPPD is per-
formed in more than 70% of cases reported in the
literature.24 We could not conclude whether TJ-
100 decreases the incidence of the paralytic ileus
after PPPD in this study because of the small sam-
ple size of the subgroup patients. Otherwise, the
lack of significant effects in our study may have
been an artifact because of the use of a modern
fast-track program, including an accelerated peri-
operative rehabilitation,7 to the placebo effect, to
tachyphylaxis, to the use of several recent innova-
tions in PD designed to prevent DGE,23,25 to the
hospital volume,26 or it may have been a true ef-
fect. Therefore, the results in this study may be
different from those in our previous study, in
which time to first flatus was significantly lower
in the TJ-100 group than in the control group:
2.6 days versus 4.7 days.14 That is, advances in
the surgery itself and modern fast track program
may have shortened the time to first flatus after
PD.
The JAPAN-PD Study was a high-quality trial in
which all the participating institutions were high-
volume centers of pancreatic surgery certified by
the Japanese Society of Hepato-Biliary-Pancreatic
Surgery, and 224 patients were randomized in
almost 10 months. The trial setting matches the
widespread use in recommendation in periopera-
tive clinical practice. Several features of the trial
decreased the risk of bias, including central
randomization, allocation concealment, masking,
and very low attrition. The risk of bias was reduced
further by pre-publication of the statistical analysis
plan.16
Our analyses also demonstrated that epidural
anesthesia was an independent risk factor for
paralytic ileus in patients who underwent PD.18
Pratt et al. reported that epidural analgesia could
not necessarily improve gastrointestinal recovery
after PD as the result of inadequate analgesia,
although a recent meta-analysis of randomized
controlled trials reported that epidural analgesia
improves recovery of bowel function.18,27 Sepra-
film has been reported to be associated with an
increased risk of abdominal abscess or sterile
inflammation,17,28 but the incidence of intraperi-
toneal abscess in our series was low, considering
the Seprafilm insertion rates (Tables I and III).
Therefore, we could not identify the reasons why
or mechanisms of how these factors induced para-
lytic ileus in the setting of the present study.Our findings suggest that the use of TJ-100 does
not improve recovery from paralytic ileus, QOL,
abdominal circumference after PD compared with
placebo, and may preclude the routine use of TJ-
100 in the clinical practice after PD operations.
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